Hikari Tsushin Inc. Purchases Shares of 7,544 Zoetis Inc. $ZTS

Hikari Tsushin Inc. acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, Holdings Channel reports. The fund acquired 7,544 shares of the company’s stock, valued at approximately $1,176,000.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Zoetis by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after acquiring an additional 330,823 shares during the period. Geode Capital Management LLC raised its stake in shares of Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares during the last quarter. Polen Capital Management LLC raised its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. BTIG Research reduced their price target on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Morgan Stanley reduced their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. reduced their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Stock Performance

NYSE ZTS opened at $116.96 on Thursday. The stock has a market capitalization of $51.54 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.31 and a beta of 0.90. The stock has a 50-day moving average of $138.98 and a 200 day moving average of $150.66. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $181.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.